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Abstract
Glioma is known as one of the most common primary intracranial tumors accounting for four-fifths of malignant brain 
tumors. There are several biological pathways that play a synergistic, pathophysiological role in glioma, including apopto-
sis, autophagy, oxidative stress, and cell cycle arrest. According to previous rese arches, the drugs used in the treatment of 
glioma have been associated with significant limitations. Therefore, improved and/or new therapeutic platforms are required. 
In this regard, multiple flavonoids and alkaloids have been extensively studied in the treatment of glioma. Berberine is a 
protoberberine alkaloid with wide range of pharmacological activities, applicable to various pathological conditions. Few 
studies have reported beneficial roles of berberine in glioma. Berberine exerts its pharmacological functions in glioma by 
controlling different molecular and cellular pathways. We reviewed the existing knowledge supporting the use of berberine 
in the treatment of glioma and its effects on molecular and cellular mechanisms.
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Introduction
Glioma is known as one of the most common primary 
intracranial tumors, which represents almost four-fifths 
of malignant brain tumors (da Silva et al. 2019). Gliomas 
are neuroectodermal in origin, arising from glial cells and 
glial precursor (Ostrom et al. 2017). Based on 2016 WHO 
update, glioma is classified by WHO as grade I-IV, while 
grade IV glioblastoma multiform (GBM) is known as the 
most common type of glioma (Howlader 2011). It has 
been reported that microglia, the purinergic P2X7 receptor 
(P2X7R) and immunocompetent cells of CNS are involved 
in the tumor progression and pathology of glioma. P2X7R 
is overexpressed in tumor cells, infiltrating microglia in 
glioma cells both in vitro and in vivo (Kan et al. 2019). 
The exosomes and miRNAs also have important roles in 
the pathogenesis of GBM (Saadatpour et al. 2016). In this 
regard, it has been shown that miR-21, miR-124, and miR-
155 are involved in the pathogenesis of glioma (Guo et al. 
2019; Masoudi et al. 2018). The up-regulation of NQO1 
decreases reactive oxygen species (ROS) and elevates the 
cell proliferation in glioma cells. In addition, overexpression 
of PINK1 represses the ROS and cell proliferation in glioma 
cells (Luo et al. 2018).
Oxidative stress induces interaction of apurinic/apyrimi-
dinic endonuclease with ectonucleotide pyrophosphatase/
phosphodiesterase 2 and pyruvate kinase M2 in glioma cells 
(Cholia et al. 2018). Hence, modulation of the oxidative 
stress can be considered as a treatment strategy for glioma 
(Marconi et al. 2019; Wu et al. 2019). Magnetic resonance 
imaging (MRI) is an ideal imaging modality for the diagno-
sis or monitoring of CNS malignancies (Senft et al. 2011).
The standard therapy of newly diagnosed GBM is the com-
bination of radiotherapy and temozolomide (TMZ) (Stupp 
et al. 2009). However, in accordance with high resistance of 
GBM to current treatments as well as the failure of prolong-
ing overall survival, new therapeutic approaches are needed 
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(Mooney et al. 2019). In a study, authors documented that 
5-ALA fluorescence-guided-surgery (5-ALA-FGS) is able 
to improve glioma treatment (Picart et al. 2019). In another 
study, redox-sensitive micelles were confirmed to be effec-
tive in the treatment of glioma (Tian et al. 2019). Moreover, 
it has been reported that medical plants and their active com-
pounds such as gynostemma pentaphyllum extract, resvera-
trol, and berberine have also beneficial effects on glioma 
cells (Schild et al. 2010; Filippi-Chiela et al. 2011; Tong 
et al. 2019).
Berberine, a protoberberine alkaloid, possesses several 
pharmacological activities, which could be used in the treat-
ment of different diseases such as cancer. Current evidences 
supported that berberine has a pivotal role in the prevention 
and treatment of brain-related disorders. Kim et al. (Kim 
et al. 2014) indicated that berberine has beneficial effects 
on the improvement of memory and motor dysfunction in 
Parkinson’s disease through the modulation of apoptotic 
pathways. Berberine was stated to exert neuroprotective 
effects in an animal model of Alzheimer’s disease through 
the regulation of amyloid precursor protein processing 
(Durairajan et al. 2012). In addition, Bhutada et al. (2010) 
found that berberine has anticonvulsant activity. Berberine 
also has anticancer activities against different cancers. Ber-
berine is able to inhibit enzyme cyclooxygenase-2 activity 
in colon cancer (Fukuda et al. 1999). In another study, it 
has been reported that berberine could decrease the expres-
sion of matrix metallopeptidase (MMP)-9 and subsequently 
reduce the cell invasion in breast cancer cells (Kim et al. 
2008). Finally, it seems that berberine exerts anti-glioma 
effects via modulating different cellular and molecular 
mechanisms, including decreasing the extracellular-signal-
regulated kinase (ERK) 1/2 activity and increasing apoptosis 
both in vitro and in vivo (Sun et al. 2018; Eom et al. 2010). 
In this regard, a better insight into anti-glioma effects of ber-
berine and involved cellular and molecular pathways could 
provide new milestones in the treatment of glioma. Herein, 
we focus on reviewing the current scenario in an attempt to 
provide interested readers with an updated view in this field.
Berberine in the Combination 
with Radiotherapy
Radiotherapy is a treatment method, which could be 
employed in various malignancies (Delaney et al. 2005). 
Radiotherapy is known as a post-surgical treatment for 
patients with malignant glioma (Walker et al. 1980). A 
systematic review indicated that the total dose delivered to 
glioma cells should ranges from 50 to 60 Gy, in the fraction 
sizes of 1.8–2.0 Gy (Laperriere et al. 2002). Different stud-
ies have indicated the beneficial effects of berberine plus 
radiotherapy in the treatment of cancers. In a study, it was 
reported that berberine increased the cytotoxicity of radia-
tion via increasing autophagy in lung cancer (Peng et al. 
2008). In another study, berberine was stated to increase the 
radiosensitivity of esophageal cancer cells via down-regula-
tion of RAD51 (Liu et al. 2011). Few studies have shown the 
effects of berberine in combination with radiotherapy on the 
treatment of glioma. Yount et al. (Yount et al. 2004) reported 
that berberine sensitized human glioma cells in response 
to ionizing radiation, which can lead to the death of GBM 
cells. Co-administration of berberine and the low energy 
laser markedly decreased the LD50 of berberine. Another 
study also indicated the treatment effect of berberine plus 
laser in glioma cell line (Chen et al. 1994). Further studies 
are needed to evaluate the effects of berberine in combina-
tion with chemotherapy and radiotherapy in the treatment 
of gliomas (Fig. 1).
The Effects of Berberine on Various 
Molecular and Cellular Mechanisms 
in Glioma
Berberine and MAPKs Pathway in Glioma Cells
There are three main subfamilies of mitogen-activated pro-
tein kinases (MAPK), including the extracellular-signal-reg-
ulated kinases (ERK), MAPK14, and the c-jun N-terminal 
kinase or stress-activated protein kinases (JNK) (Dong et al. 
2002). MAPK pathways are downstream pathways of differ-
ent growth factor receptors such as epidermal growth factor 
(EGF) (Pece and Gutkind 2000). EGF activates both PKC-
dependent and -independent pathways, thereby activating the 
Raf/MEK/ERK pathway (Chen and Davis 2003). It has been 
indicated that the Ras/Raf/MEK/ERK pathway is involved in 
the controlling of growth signals, cell proliferation, survival 
and invasion in different cancers (De Luca et al. 2012; Meier 
et al. 2005). Raf/MEK/ERK pathway is also implicated in 
the pathogenesis of glioma (See and Mukherjee 2018). In 
addition, ERK regulates cell proliferation in glioma cells 
(Jacques-Silva et  al. 2004). ERK1/2 pathway regulates 
the BCL-2 proteins to promote cell survival in tumor cells 
(Balmanno and Cook 2009). In this pathway, protein kinase 
C (PKC) is able to activate the ERK for the migration of 
glioma cells (Besson et al. 2001). Lee et al. (2005) reported 
that the Ras/MEK/ERK pathway is involved in mediating 
H2O2-induced apoptosis in human glioma cells. Moreover, 
the activation of ERK plays an important role in the media-
tion of cisplatin-induced apoptosis in human glioma cells 
(Lee et al. 2005).
Few studies have addressed the presence of potential links 
between berberine and MAPKs. Indeed, available evidences 
still are not conclusive. Berberine decreases tumor growth 
and suppresses p-ERK1/2 and Ki-67 expression in glioma 
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cells (Sun et al. 2018). In another study, berberine signifi-
cantly inhibited the Caspase-1-Mediated IL-1β and IL-18 
releasing via inhibition of ERK1/2 signaling in glioma cells 
(Tong et al. 2019). Berberine greatly reduces the epidermal 
growth factor receptor (EGFR). Downregulation of EGFR 
resulted in inhibiting the RAF-MEK-ERK signaling path-
way, but AKT phosphorylation was not changed (Liu et al. 
2015). More studies are also needed to evaluate the effects 
of berberine on different proteins of the MAPKs pathway 
in gliomas.
Berberine and MMPs Pathways in Glioma Cells
Known as zinc-dependent endopeptidases family, MMPs 
are involved in the progression of cancer via increasing the 
cancer cell growth, migration, invasion, metastasis, and 
angiogenesis (Egeblad and Werb 2002). MT1-MMP has an 
important role in the pathophysiology of human malignant 
gliomas (Forsyth et al. 1999). In a study, it was reported 
that MMP-2 is localized in vasculature cells and tumor 
cells of malignant astrocytomas as well (Sawaya et al. 
1996). MMP-2 inhibition significantly decreases tumor 
cell invasion, migration, and tumor growth in glioma cells 
(Badiga et al. 2011). In addition, these MMPs could be 
utilized as prognosis factors in the treatment of glioma 
(Thorns et al. 2003). Inhibition of MMPs can be a strategy 
for controlling cancer cells. Nyormoi et al. (2003) indi-
cated that the inhibitor of MMP-2/MMP-9 led to induc-
ing of apoptosis in cancer cells. Moreover, inhibition of 
MMPs can sensitize glioma cells to TMZ (Ulasov et al. 
2013). It has been reported that berberine has beneficial 
effects on MMPs in cancer. Berberine also prevents the 
cell migration through inhibition of MMP-1, -2, and -9 in 
gastric cancer (Lin et al. 2008a). In another study, it was 
documented that MMP-1 and MMP-9 could be inhibited 
by berberine in human breast cancer (Kim et al. 2012). 
Berberine enhances the anti-glioma effects of As2O3-; 
therefore, the treatment with As2O3 and berberine syner-
gistically decreased the activation of PKC alpha and epsi-
lon and triggered actin cytoskeleton rearrangements. Also, 
the levels of jun and myc, and MT1-MMP, and MMP-2 
reduced (Lin et al. 2008b).
Fig. 1  Schematic representation of the beneficial effects of berberine 
on different signaling pathways in glioma cells. AMPK 5′ AMP-acti-
vated protein kinase; Apaf-1 apoptotic protease activating factor-1; 
Bcl-2 B-cell lymphoma 2; Bax B-cell lymphoma 2-associated X; 
ERK extracellular-signal-regulated kinase; IL-1β interleukin-1β; IL-
18 interleukin-18; JNK c-Jun N-terminal kinases; ULK1 Unc-51-like 
autophagy activating kinase 1
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Berberine and Autophagy Pathway in Glioma Cells
Autophagy is a process of protein recycling, which initiates 
with sequestering of cytoplasmic organelles in the mem-
brane of vacuole, a process named autophagosome (Miz-
ushima 2007). PtdIns3K-Akt-mTORC1 is a very important 
signaling pathway which is related to autophagy (Wu et al. 
2009). TOR acts as the main regulator of autophagy. In addi-
tion, AMPK inhibits mTORC1 activity (Kang et al. 2011), 
which leads to suppressing ULK1 (Kang et al. 2011). ULK1 
induces the Beclin-1 phosphorylation, which can result in 
autophagy (Russell et al. 2013). The autophagy process act 
as a tumor suppressor in the early stage of tumor devel-
opment (Kondo et al. 2005). It has been showed that the 
mTOR, AKT and Ki-67/MIB-1 expression increased in 
glioma cells with a rise in grade of malignancy (Annovazzi 
et al. 2009). Autophagy could be used as a therapeutic tar-
get in the treatment of several cancers (Kondo et al. 2005); 
therefore, the induction of autophagy can promote the radio-
sensitivity in glioma cells (Palumbo et al. 2012). TMZ is 
able to exert its anti-glioma effects via inducing autophagy 
(Fan and Weiss 2011). This chemotherapy agent induces 
autophagy through ATM-AMPK-ULK1 signaling pathways 
in glioma cells (Zou et al. 2014). It has been shown that 
berberine induces autophagy in various cancers (Wang et al. 
2010; Yu et al. 2014). A study has reported that berber-
ine dephosphorylated mTOR, leading to the induction of 
autophagy. Berberine activates AMPK, which negatively 
regulates the mTOR and enhances the autophagy. In addi-
tion, berberine treatment elevated the p-Beclin-1 Ser93 in 
GBM cells. Berberine increased phosphorylated ULK1, a 
downstream target of mTOR. These signaling pathways lead 
to induction of autophagy in GBM cells (Wang et al. 2016).
Berberine and Cell Cycle Arrest in Glioma Cells
In different phases of the cell cycle (G1, S/DNA synthesis, 
G2, M/mitosis) during development, DNA is duplicated and 
the chromosomes are distributed into two daughter cells 
(Pardee 1989). Insulin-like growth factor-binding protein 
(IGFBP)-3 inhibits the cell proliferation via stimulation of 
cell cycle arrest. The expression of IGFBP-3 leads to G1 
arrest, whereby the levels of the cell cycle-regulated proteins 
including cyclin D1, cyclin D3, cyclin A, cyclin E, and cyc-
lin-dependent kinase (CDK) 2 and CDK4 may be decreased 
(Kim et al. 2010). The acetylation of p53 is also involved 
in the cell cycle arrest (Li et al. 2012). It has been shown 
that the induction of G1 arrest could contribute to control 
of cancer (Pardee 1989). Berberine promotes the cell cycle 
arrest in different cancers by decreasing cyclin D1, cyclin 
D3, cyclin A, cyclin E, and cyclin-dependent kinase (CDK) 
2 and CDK4 (Lin et al. 2006; Mantena et al. 2006). In addi-
tion, berberine induces the G1 arrest through an increase in 
the expression of P27 and a decrease in the cyclin-dependent 
kinase (CDK) 2, CDK4, cyclin E proteins, and cyclin D 
(Eom et al. 2010).
Berberine and Apoptosis Pathways in Glioma Cells
Apoptosis contributes to tumor pathogenesis by different 
pathways (Wong 2011). There is an inverse relationship 
between cell apoptosis and tumor progression (Symonds 
et  al. 1994). The changes in the ratio of pro- and anti-
apoptotic proteins are involved in cell death. There are two 
general classes of apoptosis pathways, including intrinsic 
and extrinsic ones (Fulda and Debatin 2006). Caspases are 
important parts of apoptosis pathways (Leist et al. 1997). 
Thus, the change in caspases activities affects apoptosis and 
carcinogenesis in different cancers (Ghavami et al. 2009). 
Death receptors and their ligands have important roles in 
the external apoptosis pathway, including TNF, TNFR1, 
TNFR1-associated death domain protein (TRADD), and 
TNFR-associated factor (TRAFs). In addition, FAS (CD95) 
and FASL ligand (CD95L) are members of the extrinsic 
pathway (Ashkenazi 2008). Additionally, intrinsic path-
ways are related to non-receptor proteins, which stimulate 
apoptosis through intracellular signals that influence differ-
ent targets within the cell or mitochondria. These proteins 
mainly includes the B-cell lymphoma protein 2 (Bcl-2) fam-
ily proteins and cytochrome c (Wu and Bratton 2013). Vari-
ous malignant glioma cells also express apoptotic proteins 
in intrinsic and extrinsic pathways (Song et al. 2003). It has 
been reported that apoptotic proteins are appropriate targets 
in controlling cancers (Wu and Bratton 2013).
Berberine increases the ROS and intracellular Ca (2 +) 
and also induces ER stress. In addition, this natural com-
pound markedly increases apoptosis by induction of a higher 
ratio of Bax/Bcl-2 proteins, the activation of caspase-3 and 
-9, and the cleavage of the poly(ADP-ribose) polymerase 
(PARP) (Eom et al. 2010). Berberine treatment markedly 
increases the apoptosis via induction of a higher ratio of 
the Bax/Bcl-2 proteins, mitochondrial membrane potential 
disruption, and activation of procaspase-9, caspase-3, cas-
pase-9, and poly (ADP-ribose) polymerase (PARP). Ber-
berine inhibits the glioma cell proliferation through promot-
ing G1 arrest and apoptosis (Eom et al. 2008). Berberine 
increases the production of ROS and Ca2 + in glioma cells. 
Berberine inhibits Bcl-2 but increases Bax. The caspase-8, 
-9, and -3 were activated by berberine in glioma cells (Chen 
et al. 2009).
Berberine and Arylamine N‑acetyltransferases 
in Glioma Cells
There are two related genes on chromosome 8, which 
have an important role in encoding the human arylamine 
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N-acetyltransferases (NAT1 and NAT2). NATs are known 
as polymorphic drug-metabolizing enzymes (Sim et  al. 
2014). NAT1 and NAT2 from this family are expressed in 
different tissues in the body (Windmill et al. 2000). These 
enzymes add an acetyl group from the O to the N group 
of arylacetohydroxates, which leads to the activation of 
arylamine carcinogens (Kabir and Rehman 2018). NAT1 is 
involved in cancer cell growth, since it is over€expressed 
in several cancers, leading to an increase in the resistance 
to chemotherapy (Butcher and Minchin 2012). Therefore, 
human arylamine N-acetyltransferases can be a drug target 
(Butcher and Minchin 2012). It has been reported that ber-
berine inhibits the expression of NAT in cancer (LIN et al. 
2005; Chung et al. 1999). In addition, berberine suppresses 
NAT1 in GBM cells (Wang et al. 2002). Further studies 
are needed to estimate the effects of berberine on NATs in 
gliomas.
Conclusions
Increasing evidence shows that berberine has pharmacologi-
cal effects on tumor growth, cell proliferation, glycolytic 
capacity, migration, invasion, G1 arrest, NAT1, apopto-
sis, and autophagy signaling in glioma cells. In addition, 
berberine in combination with radiotherapy has beneficial 
effects on gliomas. Therefore, berberine could be used as an 
adjuvant therapy in the treatment of glioma. Further clinical 
and pre-clinical studies are needed to assess the therapeutic 
effects of berberine in the treatment of glioma.
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